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Haploidentical transplantation can extend the opportunity for transplantation to almost all patients who lack
an HLA-matched donor. Advances in the ﬁeld of haploidentical transplantation have led to a marked decrease
in treatment-related mortality, allowing investigators to focus on developing rationale pre- and peri-
remission therapies aimed at preventing disease relapse after transplantation. Because of widespread
availability, low treatment-related mortality, and cost, haploidentical donors may become the preferred
“alternative” donors for allogeneic hematopoietic stem cell transplantation. One of the major advantages of
using a related donor is the possibility of collecting or generating additional cellular products from the same
immediately available donor, which will not be rejected. Infusion of these cells in the peri-transplantation
period, derived from the same immune system, is opening the possibility of markedly enhancing the anti-
tumor effects of the graft and hastening immunologic reconstitution after transplantation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION have a haplotype-matched related donor in the immediate
Allogeneic hematopoietic stem cell transplantation
(AHSCT) is a potential curative treatment for patients with
advanced hematologic malignancies. However, donor
availability remains one of the major limitations to
extending this treatment modality to all patients in need.
Although an HLA-matched sibling is the preferred donor,
only a minority of patients will have such a donor available
[1]. An HLA-matched unrelated donor has been considered
the next best option; however, identiﬁcation of a matched
unrelated donor is challenging [2]. Also, the unrelated
donor search and procurement of stem cell product take
much longer than when using a related donor. Many pa-
tients urgently need transplantation to prevent disease
relapse, and a prolonged unrelated donor search is not
feasible. One HLA haplotypeematched ﬁrst-degree relative,
as a related transplantation, is the most accessible stem cell
source that is also widely available, as most patients willedgments on page 1718.
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ty for Blood and Marrow Transplantation.family, typically a parent, child, or sibling. In addition, an
important advantage that has recently come to the forefront
is the immediate availability of the same donor to collect or
generate additional cells, such as T cells or T cell subsets,
such as natural killer (NK) cells, to enhance antitumor ef-
fects of the graft [3]. This may provide a signiﬁcant advan-
tage to haploidentical stem cell transplantation (HaploSCT),
which, in addition to low nonrelapse mortality (NRM),
lower cost compared with unrelated donor transplantation,
and widespread availability, may be an ideal setup for
cellular therapy with cells collected from the same donor
that may not be rejected, as they are part of the same im-
mune system, and, when infused early after trans-
plantation, could enhance the antitumor effects of the graft
and improve immunologic reconstitution.
Here, we review the use of HaploSCTas a platform to apply
post-transplantation cellular therapy with cells collected or
generated from the same donor to enhance the graft-versus-
tumor (GVT) effect and we discuss current and anticipated
developments using cellular therapy in this setting.METHODS OF HAPLOIDENTICAL TRANSPLANTATION
HaploSCT, initially performed in late 1970s using unmanipulated
T cellereplete (TCR) stem cell grafts and conventional graft-versus-host
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rejection in most patients [4,5]. Early evidence suggested that the T cells in
the graft are responsible for causing aGVHD [6,7]. In an early attempt to
minimize T cell alloreactive reactions across the HLA barrier and decrease
the risk of GVHD, complete ex vivo T cell depletion (TCD) of the graft was
developed. Unfortunately, extensive T cell depletion was associated with an
increased risk of graft failure [8-11] and a signiﬁcant delay in immunologic
reconstitution was observed, associated with a higher risk of opportunistic
infections after transplantation [12,13].
Several novel approaches have been subsequently developed to partially
deplete T cells from the graft with the goal of preserving immunity and GVT
effects while selectively eliminating the cells mostly responsible for GVHD
(Table 1). Some, if not all, of these methods may become a platform for post-
transplantation cellular therapy.
Co-infusion of Regulatory T Cells and Conventional T Cells
Regulatory T cells (Tregs) deﬁned by CD4þCD25þ and the transcription
FOXP3 expression, suppress autoreactive lymphocytes and control innate
and adaptive immune responses. In preclinical models, Tregs suppressed the
early expansion of alloreactive donor T cells and their capacity to induce
GVHD without abrogating their GVT effect [14,15] and when coinfused with
CD4þCD25- conventional T cells (Tcons), immune recovery was accelerated
[16]. Given these observations, immunotherapy with Tregs and Tcons has
been explored for clinical applications. The Perugia group treated 28 pa-
tients with high-risk hematologic malignancies conditioned with ﬂudar-
abine, cyclophosphamide (CY), total body irradiation (TBI), and thiotepa
before haploidentical donorederived Tregs infusion, followed by the TCD
stem cell graft combined with Tcons infusion, with a ratio of Tcons to Tregs
about 1:2. No GVHD prophylaxis was administered. Twenty-six of the
28 patients achieved primary engraftment and only 2 patients developed
aGVHD. No patient had chronic GVHD (cGVHD). Even though immune re-
covery appeared rapid, NRM occurred in 13 of the 26 evaluable patients,
including 8 from infection. Long-term results of this study have conﬁrmed
low GVHD and relapse incidences; however, NRM remains a concern [17].
Photodepletion of Alloreactive T Cells
This approach aims to selectively deplete Tcells that react against recipient
alloantigens to prevent GVHD, yet preserve tumor-speciﬁc and
pathogen-reactive T cells. It requires the alloactivation of donor T cells by
patient-derived antigen-presenting cells. Alloreactive donor T cells are then
targeted by their expression of surface activation markers, proliferation in a
mixed leukocyte reaction, or the preferential retention of photoactive dyes.
One of the methods to eliminate these alloreactive donor T cells is ex vivo
photodepletion. This strategy’s principle is that alloreactive T cells uptake and
accumulate the TH9402 compound. Then, these cells are lysed after exposure
to a speciﬁc wavelength of visible light. This approach would spare resting
T cells to ﬁght infections. This method also has been found to transform non-
Tregs to Treg cells and can help prevent GVHD in HaploSCT patients [18].
This approach is now being studied in a multi-institutional phase II setting.
Depletion of Alpha-beta and CD19þ T Cells
The ab T cell receptorepositive T cells are a major content of the T cell
population and responsible for the occurrence of GVHD as they recognize al-
loantigens inMHCdependentmanner [19]. On the other hand, innate like gd T
cells are capable of directly recognizing their targets in an MHC-independent
manner, thereby allowing them to respond to malignancy cells without
recognition of alloantigens that could result in GVHD. Several studies have
shown that patients who develop increased numbers of donor-derived
circulating gd T cells after HaploSCT or partially mismatched AHSCT experi-
ence prolonged survival [20,21]. These ﬁndings have led to the rationale of
selective elimination of ab T cells while preserving gd T cells with the aim of
reducing GVHD without abrogating GVT effect. Early results in a pediatric
population with nonmalignant diseases are very encouraging. Twenty-three
children received HaploSCT after ex vivo elimination of ab T cells without
post-transplantation GVHD prophylaxis. Sustained engraftment in the greatTable 1
Current Selective Approaches to Haploidentical Transplantation
Approach Rationale and Advantages
Tregs and Tcons coinfusion [14-17] Prevent GVHD by Tregs while prom
Photodepletion of alloreactive T cells [18] Ex vivo depletion of alloreactive T c
Selective ab T cell depletion [19-21] Removing ab T cells that are most r
immune-like response capability w
High-dose PTCY [22-29] Eliminates early alloreactive T cells;
acceptable rates of GVHD; lower comajority of patients, rapid immune reconstitution, and low incidence of NRM
were observed in this study. With the median follow-up of 18 months,
disease-free survival was 90% [30]. These patients did not receive additional
post-transplantation immune suppression and had a low incidence of aGVHD.
Studies evaluating this approach in adult patients are ongoing. The biggest
advantage of this approach appears to be the possibility of avoiding
post-transplantation immunosuppression.
Post-transplantation CY for GVHD Prevention
CY is a highly immunosuppressive alkylating agent, which has been
incorporated in various conditioning regimens for AHSCT. High-dose post-
transplantation CY (PTCY) has been used to selectively deplete alloreactive
T cells after TCR HaploSCT. This approach is based on an observation that CY
can promote tolerance to allogeneic MHC-mismatched skin grafts in mice
[31]. In animal models of AHSCT, CY administered on day þ3 allowed stable
engraftment of MCH-incompatible cells and attenuated lethal and nonlethal
GVHD [32]. Moreover, Ross et al. demonstrated that alloreactive or stimu-
lated T cells, which are responsible for causing graft rejection and GVHD, are
more susceptible to the cytotoxic effect of CY than resting or memory T cells
[33]. However, concerns about its myelotoxicity have deterred clinical
application of high-dose PTCY. Kastan et al. have shown that human he-
matopoietic progenitor cells express high levels of cytoplasmic aldehyde
dehydrogenase, which makes them resistant to the cytotoxic effect of CY
[34]. Moreover, both preclinical and clinical studies have demonstrated the
resistance of Tregs to CY through expression of aldehyde dehydrogenase,
which may contribute to GVHD prevention in this setting [22,35]. Based on
its ability to induce maximal immunosuppression without myeloablation,
several clinical trials have been performed at multiple transplantation
centers to assess the efﬁcacy of PTCY administration to prevent GVHD. An
initial phase 1 clinical trial showed safety and efﬁcacy of PTCY in preventing
graft rejection and GVHD after nonmyeloablative, TCR bone marrow trans-
plantation from haploidentical donors. This protocol used a conditioning
regimen of ﬂudarabine, CY, and 2 Gy TBI, initially with only 1 dose of PTCYof
50mg/kg on dayþ3 [23]. The regimenwas subsequentlymodiﬁed by adding
1 more dose on day þ4. A remarkably low incidence of aGVHD, cGVHD, and
NRM were observed in this study. However, more than one half of the pa-
tients relapsed after 1 year after transplantation [24]. A recent study by
McCurdy et al. has shown that disease aggressiveness is the main factor for
relapse and survival after nonmyeloablative HaploSCT with PTCY [25]. To
reduce the risk of relapse, especially for patients with high-risk malig-
nancies, a more intense conditioning has been investigated by several
groups. In a recent study by Solomon et al., 30 patients with advanced he-
matologic malignancies were treated with a conditioning regimen using
ﬂudarabine and fractionated TBI (total dose 1200 cGy) and a peripheral
blood graft. Donor engraftment occurred in all patients; the cumulative
incidence of grade II to IV and III and IV aGVHD was 43% and 23%, respec-
tively; and NRM at 2 years was only 3%. With a median follow-up of
24 months, disease-free survival was 73% at 2 years [26]. Our group recently
reported the outcomes of the ﬁrst 100 patients treated at MD Anderson
Cancer Center using a ﬂudarabine, melphalan, thiotepa conditioning
regimen. The 3-year progression-free survival rates for patients with
myeloid and lymphoid malignancies were 56% and 62%, respectively, with
1-year NRM rates of 12% and 22%, respectively [27]. Other groups reported
alternative conditioning regimens with similar outcomes [28]. Collectively,
these clinical data suggest that the use of PTCY with tacrolimus and myco-
phenolate mofetil is very effective in controlling GVHD in HaploSCT, can be
used with many conditioning regimens, and because of the low NRM,
could serve as a platform for cellular therapy after transplantation. These
improved outcomes were found to be signiﬁcantly better compared with
complete ex vivo TCD HaploSCT because of more rapid immune reconsti-
tution and lower incidences of severe aGVHD, cGVHD, and NRM [29].
Nonetheless, it remains unclear how TCR HaploSCT with PTCY will compare
with other in vivo and ex vivo methods of partial TCD [36].
A number of other methods to control alloreactivity in haploSCT have
been developed by other investigators from different institutions, but are
not discussed in this review.oting immune reconstitution by addition of Tcons
ells with TH9402 that accumulates in activated T cells
esponsive for aGVHD; remaining gd T cells are thought to have an innate
ithout inducing GVHD.
rapid immune recovery with low rate of infectious complications;
st
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With signiﬁcant improvement in NRM, disease relapse
has become the most important cause of treatment failure in
patients undergoing HaploSCT, similar to matched trans-
plantation. Several strategies have been used and novel ap-
proaches are being explored to prevent and treat disease
relapse after transplantation (Table 2). This may offer a
unique opportunity, probably for the ﬁrst time since the
beginning of allogeneic transplantation, to greatly enhance
the antitumor effects of the graft when administered early
after transplantation. Current and foreseeable cell therapy
approaches that could be applied after HaploSCT are outlined
below.
Unmodiﬁed Donor Lymphocyte Infusion (DLI)
Donor lymphocyte infusion (DLI) has been used primarily
as a therapeutic option to treat disease relapse after HLA-
matched sibling or unrelated donor AHSCT. Considering the
ready availability of haploidentical donors, donor lympho-
cytes can be easily obtained and infused to the recipients to
prevent or treat early disease relapse. A higher risk of severe
aGVHDwhen using haploidentical DLI (haploDLI) is the most
important concern. However, several studies did not showan
increase risk of aGVHD after haploDLI compared with DLI
from HLA-matched donors, probably because the tolerizing
effect on donor cells had already occurred. An early study by
Huang et al. used granulocyte colonyestimulating factore-
primed therapeutic haploDLI in 20 patients with relapse af-
ter transplantation, with the median cell dose of 61  106
CD3þ Tcells/kg. The incidences of grade III and IV aGVHD and
cGVHD were 30% and 64%, respectively [37]. A more recent
report from the same group described the experience with
haploDLI administered to 124 patients after TCR HaploSCT.
The cumulative incidence of aGVHD (53.2% for grade II to IV
and 28.4% for grade III to IV) was reduced with post-DLI
GVHD prophylaxis [38]. However, with a dose-escalated
approach using a lower starting DLI dose, the incidence
aGVHD appears to be lower and well tolerated. The Johns
Hopkins group administered 52 doses of haploDLI to 40 pa-
tients with hematologic malignancies treatedwith PTCYwho
relapsed after HaploSCT. Using dose escalation, they started
with 1 105 CD3þ T cells/kg of recipient’s ideal body weight.
Themajority of patients (72.5%) received 1106 CD3þ/kg DLI
dose. Overall,12 (30%) patients responded to haploDLI and all
achieved a complete remission, with a median response
duration of 12 months. aGVHD occurred in only 25% and
grade III and IV aGVHD occurred in 15% [39]. This group
recommended 1106 CD3þ/kg as starting dose. This was the
ﬁrst study to conﬁrm the feasibility of DLI in patients
receiving PTCY as GVHD prevention. In a similar study by
Ghiso et al. using DLI from haploidentical sibling donors for
treatment of 108 patients who relapsed after HaploSCT, the
starting DLI dose was 1 104 or 1 105 CD3þ T cells/kg. The
cumulative incidence of aGVHD grade II to IV was only 14%Table 2
Post-transplantation Cellular Therapy Approaches Aimed at Decreasing Disease Re
Approach Advantages and Limitations
Unmodiﬁed DLI [37-40] Increase graft-versus-maligna
Unmodiﬁed DLI with a “safety switch” [41-46] Increase graft-versus-maligna
gd donor T cell infusion [47-55] Infusion of selected gamma-d
T cells with CARs [56-58] T cells engineered to recogniz
B cell lymphoid malignancies
Infusion of ex vivoeexpanded NK cells [59-64] Potential graft-versus-maligna
NHL indicates non-Hodgkin lymphoma.and none of the patients developed cGVHD. The response
rates were 45%, 33%, and 70% in patients with molecular
relapse and hematologic relapse of leukemia and Hodgkin’s
disease, respectively [40]. Results from these studies suggest
that dose-escalated DLI can be safely administered in pa-
tients who relapse after HaploSCT, as no signiﬁcant increase
GVHD was observed in these patients compared with DLI
administered for HLA-matched transplantations. The use of
unmodiﬁed DLI with a “safety switch,” as described below, to
prevent disease relapse in patients with advanced hemato-
logical malignancies is being tested in clinical trials.
Unmodiﬁed DLI with a “Safety Switch”
A higher risk of aGVHD is the main limitation of early
administration of an unmodiﬁed DLI. To control the devel-
opment of severe aGVHD after transplantation, infused
T cells can be genetically modiﬁed ex vivo to express a spe-
ciﬁc suicide gene, which may be turned on to induce cell
apoptosis if GVHD occurs. The administration of donor T cells
with a “safety switch” can help prevent relapse when
administered earlier after transplantation and may accel-
erate immune reconstitution. The safety and efﬁcacy of this
approach have been investigated in several preclinical and
early clinical studies [41-44]. In a phase 1/phase 2 clinical
trial by Ciceri et al., donor T lymphocytes engineered to ex-
press herpes simplex thymidine-kinase suicide gene (TK
cells) were infused in patients with high-risk leukemia who
underwent HaploSCT with TCD peripheral blood grafts. T cell
apoptosis can be triggered by the use of gancyclovir if the
patients developed GVHD. No GVHD prophylaxis was used
after transplantation. Of 28 patients, 22 successfully engraf-
ted with TK cells. Improvement of immune response against
cytomegalovirus and Epstein-Barr virus was seen after
TK cell infusions. Ten patients developed aGVHD, which was
abrogated by using gancyclovir. No acute or chronic adverse
events were related to the gene-transfer procedure [45].
Correspondingly, a study by Vago et al. has conﬁrmed that
TK cell infusion can drive the recovery of thymic activity in
adults patients treated with TCD haploSCT, leading to im-
mune reconstitution. In this study, 11 patients developed
GVHD after TK cell infusion and all of them achieved com-
plete resolution of all signs and symptoms by the activation
of the suicide gene in TK cells through intravenous admin-
istration of gancyclovir [46]. However, gancyclovir is a drug
commonly used to treat cytomegalovirus reactivation in
AHSCT; thus, using this drug might not be optimal. Although
the expression of the gene-encoding herpes simplex virus TK
has shown promise as a safety switch, its mechanism of ac-
tion requires interference with DNA synthesis. Therefore, the
cell killing may take several days and be incomplete,
resulting in a delayed clinical beneﬁt. The Baylor group
developed an alternative approach by using T cells engi-
neered to express caspase 9, which can be induced by using a
dimerizing agent, AP1903. These inducible caspase 9 T cellslapse after Haploidentical Transplantation
ncy effect; nonselective
ncy effect; control of GVHD, if develops; nonselective
elta T cells; no GVHD potential; unclear efﬁcacy
e speciﬁc antigens (eg, CD19) provides graft-versus-malignancy effect for
(ALL, NHL); efﬁcacy demonstrated in small series; no GVHD potential
ncy for myeloid malignancies; no GVHD; efﬁcacy unclear
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who received AHSCT with TCD. AP1903 administration
rapidly resolved GVHD without a signiﬁcant effect on anti-
viral immune reconstitution [44,65]. Ongoing and future
studies are investigating the efﬁcacy of this approach in
preventing disease relapse after HaploSCT.
Gamma-delta Donor T Cell Infusion
The gd T cells are a subset of T cells, accounting for 1% to
10% of circulating human T lymphocytes, largely out-
numbered by T cell receptor ab CD4þ and CD8þ T cells [66].
Unlike ab T cells, gd T cells have a directed cytotoxic effect on
target cells, independent from antigen presentation via HLA
molecules, which allows them to target and kill tumor cells
without causing GVHD. Preclinical studies have shown that
donor gd T cells are able to promote alloengraftment and the
GVT effect, yet they did not cause lethal GVHD in mice that
underwent transplantation with MHC-incompatible TCD
marrow grafts [47-49]. However, in a clinical setting,
immunotherapy with gd T cells requires their activation and
expansion, as they constitute only a small percentage of
circulating T cells. Aminobisphosphonates, eg, zoledronic
acid, or synthetic phosphoantigens, eg, bromohydrin pyro-
phosphate and 2-methyl-3-butenyl-1-pyrophosphate, have
been used with promising results for gd T cells expansion in
clinical settings [50-52].
Also, many clinical studies have demonstrated that gd
T cells as immune therapy for hematologic malignancies is a
well-tolerated and feasible method, with objective tumor
responses in patients with various hematologic malignancies
[21,52,53,67,68]. In the HaploSCT setting, Airoldi et al.
assessed functional and phenotypic characteristics of
gd T cells after HaploSCT using ab T cells and CD19þ
B celledepleted graft in 27 childrenwith either malignant or
nonmalignant disorders. This group demonstrated that se-
lective depletion of ab T cells from haploidentical peripheral
blood stem cells enhances the functional and phenotypic
reconstitution of gd T cells. Further, the Vd2 subset of gd
Tcells are expanded in vitro after exposure to zoledronic acid
and efﬁciently lyse primary lymphoid and myeloid blasts
[54]. These new insights may have important implications
for the use of gd T cell infusion after transplantation for
preventing or treating disease relapse, especially after
partially TCDehaploidentical grafts, where donor gd T cells
can easily be obtained using the same immunomagnetic
procedure as the ab TCD grafts.
Infusion of T Cells with Chimeric Antigen Receptors
(CARs)
This approach offers a targeted antitumor effect without
added risk of developing GVHD by using T cells that are
engineered to express a chimeric receptor with an extracel-
lular domain that can recognize a speciﬁc antigen on the
tumor cells and an intracellular domain that can activate the
cytotoxic T cells [69]. CARs have been used successfully in
tumors that express the CD19 antigen, such as B cell acute
lymphoblastic leukemia (ALL) or B cell non-Hodgkin lym-
phomas. Kochenderfer et al. reported outcomes of 10 pa-
tients who received anti-CD19 CARs for post-transplantation
relapsed B cell malignancies. Three patients had regression
of their malignancies and none of the patients developed
GVHD after CARs infusion [56]. Maude et al. conducted a pilot
clinical trial using autologous Tcells transduced with a CD19-
directed CAR (CTL019) lentiviral vector in 30 patients with
relapsed or refractory ALL. Twenty-seven of 30 patients (90%)were in a morphologic remission 1 month after the infusion
of CTL019. Of those who had a morphologic remission, 22
patients had negative minimal residual disease. These in-
vestigators also demonstrated that CTL019 cells proliferated
in vivo and were detectable in the blood, bone marrow, and
cerebrospinal ﬂuid of patients who responded [57]. We
are exploring the use of haploidentical donorederived CAR
T cells generated using the “Sleeping Beauty” system and
administered early after HaploSCT to prevent disease relapse,
as a part of a multiarm clinical trial [58]. Four HaploSCT
recipients received CAR T cells in escalating doses up to
1  107/m2 so far; 3 with ALL and 1 with primary induction
failure large B cell lymphoma who never achieved remission
after multiple different courses of chemotherapy. CAR T cells
were administered 6 to 12 weeks after stem cell infusion.
CAR Tcells were detected in all patients 2 to 4weeks after the
infusion. All patients received mycophenolate mofetil until
dayþ90 and tacrolimus until 6 months after transplantation.
Overall, 3 of 4 patients remain in remission at last follow-up.
These results are very promising and show that allogeneic
CAR T cell therapy can be safely administered early after
HaploSCT without signiﬁcant GVHD in the presence of
nonsteroid-based immunosuppression.
Infusion of Ex VivoeExpanded NK Cells
NK cells are part of the innate immune system involved in
identifying and killing tumor cells or virally infected cells. NK
receptors speciﬁc for HLA class I molecules, called killer
immunoglobulin-like receptors (KIRs), play a major role in
the antitumor effect in AHSCT. NK cells express KIRs, which
mediate inhibition by recognizing speciﬁc HLA class I alleles.
Missing expression of the KIR ligand on mismatched allo-
geneic cells can, therefore, enhance NK cell alloreactivity
[70-73]. In HaploSCT, HLA mismatches can trigger donor-
versus-recipient NK cell alloreactivity without causing
GVHD, as they target hematopoietic cells sparing other body
organs, making them ideal in the HaploSCT setting [74]. This
concept was ﬁrst observed in the TCD HaploSCT setting,
where patients with a KIRmismatch had a lower incidence of
relapse [72]. In both animal and clinical studies, it has been
demonstrated that donor NK cells inhibit donor T cell pro-
liferation and increase apoptosis, resulting in reduced
severity and delayed progression of GVHD [75-77].
Several studies suggested a lower risk of relapse with
donors who possess speciﬁc activating KIR genes, such
as KIR2DS1, KIR2DS2, or the KIR “B” haplotype [76,78-80].
There is currently great interest in identifying HaploSCT
donors with a KIR mismatch to possibly maximize the GVT
effects and in exploring the potential beneﬁt of using NK cells
for adoptive cellular immunotherapy to prevent disease
relapse, which has been used successfully in children with
acute myeloid leukemia [81]. However, the major obstacle
for NK cell therapy, especially in adult patients, is the rela-
tively low number of NK cells that can be obtained from the
donor, and much like with T cell therapy, in which a higher
cell number proportional to the estimated number of tumor
cells is needed, it is likely that higher numbers of NK cells are
needed for effective NK cell therapy [82]. In addition, mul-
tiple studies have shown that NK cells generated early after
transplantation have an immature phenotype and a relative
lack of function [83-86]. To address these problems and
increase the cytotoxic effect of NK cells, various ex vivo
expansion methods have been developed and tested in pre-
clinical and early clinical studies [59-63]. Choi et al. gener-
ated donor NK cells from the CD3þ celledepleted portion of
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using human IL-15 and -21. Expanded doses of NK cells up
to 2  108/kg were then infused into 41 patients with
hematologic malignancies who underwent HaploSCT after
reduced-intensity conditioning containing busulfan, ﬂudar-
abine, and antithymocyte globulin. The researchers observed
no signiﬁcant difference in the cumulative incidences of
major transplantation outcomes when comparing themwith
31 historical control patients who had undergone HaploSCT
using the same conditioning regimen without high-dose NK
cell infusion. However, a reduction in leukemia progression
was seen in patients who received a high NK cell dose and
the authors found that post-transplantation NK cell infusion
was an independent predictor for less leukemia progression
[63]. Although these results are encouraging, they are not
conclusive of a beneﬁcial effect in reducing relapse or
improving survival; further studies are needed.
We are currently exploring infusion of ex vivoeexpanded
NK cells using the mb-IL21 method developed at MD
Anderson Cancer Center in patients treated with a HaploSCT
in a phase 1/phase 2 clinical trial that is evaluating the safety
and efﬁcacy of these NK cells to prevent disease relapse in
patients with advanced myeloid malignancies when
administered early after transplantation. Six patients were
treated on study with escalating doses between 1  105 to
1  107/kg. All engrafted and no adverse effects of aGVHD
were observed, compared with a recent published report in
which aGVHD was a major complication after NK cell infu-
sion, especially in unrelated donors [64].
CONCLUSIONS
The ﬁeld of HaploSCT has grown substantially over the
past several years. A signiﬁcant advantage of using hap-
loidentical donors is the possibility of using cells obtained
from the same donor and immune system, which represents
a major opportunity of greatly enhancing the antitumor
effects of the graft and potentially improving immunologic
reconstitution, key components of a successful allogeneic
hematopoietic stem cell transplantation.
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